Clinical trials: in Czechia
Plasma Cell Myeloma Recurrent
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
This will be randomized, multicenter, Phase 3, open-label study evaluating subcutaneous (SC) vs intravenous (IV) administration of isatuximab in combination with pomalidomide and dexamethasone (Pd) in RRMM patients (study…
- Trial name
- IRAKLIA (NCT05405166)
- Testing
- Isatuximab IV, Isatuximab SC, Dexamethasone
- Where
- 128 sites in United States, Argentina and 19 more
- Volunteers
- 531 people
- Sponsor
- Sanofi
Psoriatic Arthritis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).
- Trial name
- NCT06624228
- Testing
- Bimekizumab, Risankizumab
- Where
- 127 sites in United States, Australia and 9 more
- Volunteers
- 553 people
- Sponsor
- UCB Biopharma SRL
Sepsis, Acute Kidney Injury
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
This study will enroll adults aged 18 to 80 years diagnosed with sepsis due to a suspected or confirmed bacterial infection, within 7 days of being admitted to the hospital, and who have also developed acute kidney injury within…
- Trial name
- SERENIA (NCT07215702)
- Testing
- AZD4144
- Where
- 74 sites in United States, Argentina and 12 more
- Volunteers
- 124 people
- Sponsor
- AstraZeneca
Influenza, Human
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
This Phase 3 study is a randomized, observer-blind study of MF59-adjuvanted influenza vaccine (aQIV or aTIV) compared with a non-adjuvanted influenza vaccine (QIV or TIV) in adults ≥65 years of age.
- Trial name
- NCT06087640
- Testing
- aQIV or aTIV, QIV or TIV
- Where
- 255 sites in United States, Australia and 19 more
- Volunteers
- 38,769 people, healthy volunteers welcome
- Sponsor
- Seqirus
Scleroderma, Diffuse
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis…
- Trial name
- NCT06655896
- Testing
- rapcabtagene autoleucel, rituximab
- Where
- 93 sites in United States, Argentina and 20 more
- Volunteers
- 96 people
- Sponsor
- Novartis Pharmaceuticals
Hodgkin Lymphoma
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
Researchers are looking for a way to treat classical Hodgkin lymphoma (cHL) that is relapsed (the cancer has come back after treatment) or refractory (current treatment has stopped working to slow or stop cancer growth).
- Trial name
- NCT05508867
- Testing
- favezelimab/pembrolizumab, bendamustine, gemcitabine
- Where
- 105 sites in United States, Argentina and 18 more
- Volunteers
- 203 people
- Sponsor
- Merck Sharp & Dohme LLC
Heart Failure, Heart Failure Preserved Ejection Fraction
Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)
The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with preserved ejection fraction
- Conditions
- Heart Failure, Heart Failure Preserved Ejection Fraction, Cardiovascular Diseases, Heart Diseases
- Trial name
- Cycle-2-PEF (NCT06215586)
- Testing
- Tovinontrine (CRD-750)
- Where
- 84 sites in United States, Australia and 13 more
- Volunteers
- 303 people
- Sponsor
- Cardurion Pharmaceuticals, Inc.
Ulcerative Colitis
A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with moderately to severely active Ulcerative Colitis (UC).
- Trial name
- ARTEMIS-UC (NCT04996797)
- Testing
- Tulisokibart, Companion Diagnostic (CDx) Testing
- Where
- 88 sites in United States, Australia and 10 more
- Volunteers
- 178 people
- Sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Overactive Bladder Syndrome
Efficacy and Safety of Peroneal Electric Transcutaneous Neuromodulation in the Real-world Clinical Practice
The aim of the project is to study neuromodulation treatment in patients with idiopathic overactive bladder syndrome (OAB) in real clinical practice.
- Trial name
- NCT07796958
- Testing
- Peroneal eTNM
- Where
- Czechia
- Volunteers
- 300 people
- Sponsor
- University Hospital Ostrava
Intracranial Hemorrhages, Atrial Fibrillation
EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)
To assess whether edoxaban (60/30 mg daily) compared to non-antithrombotic medical therapy (either no antithrombotic therapy or antiplatelet monotherapy) reduces the risk of stroke (composite of ischemic, hemorrhagic and…
- Trial name
- ENRICH-AF (NCT03950076)
- Testing
- Edoxaban, Non-anticoagulant medical therapy
- Where
- 152 sites in United States, Argentina and 13 more
- Volunteers
- 948 people
- Sponsor
- Population Health Research Institute
Type 2 Diabetes, Cardiovascular Risk
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
This study is being conducted to find out how well zenagamtide works and how safe it is compared to insulin glargine in participants with type 2 diabetes who are at higher risk of heart and blood vessel problems and are already…
- Trial name
- AMBITION 7 (NCT07797335)
- Testing
- Zenagamtide, Insulin glargine U-100
- Where
- 330 sites in United States, Argentina and 14 more
- Volunteers
- 1,778 people
- Sponsor
- Novo Nordisk A/S
Heart Failure, Heart Failure With Reduced Ejection Fraction
A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)
The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with reduced ejection fraction.
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Cardiovascular Diseases, Heart Diseases
- Trial name
- Cycle-1-REF (NCT06215911)
- Testing
- Tovinontrine (CRD-750)
- Where
- 139 sites in United States, Australia and 17 more
- Volunteers
- 557 people
- Sponsor
- Cardurion Pharmaceuticals, Inc.
Friedreich Ataxia
Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study
This project is a global, multicenter, prospective, longitudinal, observational natural history study that can be used to understand the disease progression and support the development of safe and effective drugs and biological…
- Trial name
- UNIFAI (NCT06016946)
- Where
- 34 sites in United States, Australia and 15 more
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Friedreich's Ataxia Research Alliance
Hereditary Spastic Paraplegia, Spastic Ataxia
TreatHSP Platform: Adaptive Natural History Platform for Ataxias, HSPs, and Spastic Ataxias
Ataxias, hereditary spastic paraplegias (HSP), and spastic ataxias (collectively referred to as SPAX diseases) are rare neurological conditions that cause progressive problems with walking, balance, coordination, and daily…
- Trial name
- TreatHSP (NCT07798674)
- Where
- 30 sites in Austria, Czechia and 7 more
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Heidelberg University
Stroke (CVA) or TIA
Stroke Care During the COVID-19 Pandemic
Background: The SARS-CoV-2 pandemic led to substantial changes in the allocation of healthcare resources and affected the behavior of patients experiencing stroke symptoms.
- Trial name
- NCT07795021
- Testing
- statistical analysis
- Where
- 4 sites in Czechia, Germany and 2 more
- Volunteers
- 40,000 people
- Sponsor
- Dr. Yaroslav Winter
Warm Autoimmune Hemolytic Anemia
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia
The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA).
- Trial name
- ENERGY (NCT04119050)
- Testing
- M281
- Where
- 171 sites in United States, Brazil and 17 more
- Volunteers
- 118 people
- Sponsor
- Janssen Research & Development, LLC
COPD, Smoking
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
The purpose of this randomized study is to demonstrate direct clinical benefit, i.e., observed benefits in how humans with COPD feel in terms of symptoms (e.g., cough frequency, shortness of breath, and other respiratory…
- Conditions
- COPD, Smoking, Tobacco Use
- Trial name
- NCT07108166
- Testing
- Cigarette, THS
- Where
- 112 sites in United States, Bulgaria and 7 more
- Volunteers
- 290 people
- Sponsor
- Philip Morris Products S.A.
Coeliac Disease, Celiac Disease
A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
This is a Phase 2a/b, randomized, double-blind, placebo-controlled, parallel-group, 6-arm study to evaluate the efficacy and safety of amlitelimab in adult participants with non-responsive celiac disease (NRCD) who are on a…
- Trial name
- NCT06557772
- Testing
- Amlitelimab, SIGE, Gluten-free product (GFP)
- Where
- 118 sites in United States, Argentina and 19 more
- Volunteers
- 229 people
- Sponsor
- Sanofi
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
The purpose of Study ALXN2220-ATTRCM-302 is to evaluate the long-term safety, tolerability and efficacy of ALXN2220 in adult participants with ATTR-CM treated with ALXN2220 in addition to SoC who have completed Study…
- Trial name
- LTSAFE-ALXN (NCT07789483)
- Testing
- ALXN2220
- Where
- 195 sites in United States, Argentina and 25 more
- Volunteers
- 1,180 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
B-cell Malignancies
A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib
The purpose of this study is to learn about the long-term safety and effectiveness of zanubrutinib in people with B-cell cancers who took part in an earlier zanubrutinib study.
- Trial name
- NCT04170283
- Testing
- Zanubrutinib, Tislelizumab
- Where
- 153 sites in United States, Australia and 16 more
- Volunteers
- 955 people
- Sponsor
- BeOne Medicines
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.